Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

ClinicalTrials.gov ID: NCT01582061

Public ClinicalTrials.gov record NCT01582061. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).

Study identification

NCT ID
NCT01582061
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
104 participants

Conditions and interventions

Interventions

  • Pasireotide sub-cutaneous Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 15, 2011
Primary completion
Jan 25, 2017
Completion
Jan 25, 2017
Last update posted
Jun 18, 2018

2011 – 2017

United States locations

U.S. sites
17
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
Advanced Research, LLC Peoria Arizona 85381
St Josephs Hospital & Medical Center St Joes Phoenix Arizona 85013
University of California at Los Angeles UCLA Tiverton Los Angeles California 90095
LA Biomedical Research at Harbor UCLA Medical Center Torrance California 90502
Emory University School of Medicine Atlanta Georgia 30322
John H Stroger Jr Hospital of Cook County Chicago Illinois 60644
University of Maryland Medical Center Baltimore Maryland 21201
Diabetes and Endocrinology Associates, PC Omaha Nebraska 68131
University of Nebraska Medical Center Omaha Nebraska 68198
University of New Mexico Hospital UNM Albuquerque New Mexico 87106
Mount Sinai School of Medicine New York New York 10029
Oregon Health and Science University OHSU 5 Portland Oregon 97239
University of Pennsylvania Medical Center Univ Penn Philadelphia Pennsylvania 19104
Allegheny Endocrinology Associates Pittsburgh Pennsylvania 15212
Mid South Endocrine Associates Nashville Tennessee 37203
Vanderbilt University Medical Center Nashville Tennessee 37212
Swedish Cancer Institute Swedish Cancer Institute (SC) Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01582061, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 18, 2018 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01582061 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →